These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 38587361)
1. Update on FDG-PET in pediatric lymphoma. Kurch L; Kluge R Q J Nucl Med Mol Imaging; 2024 Mar; 68(1):58-69. PubMed ID: 38587361 [TBL] [Abstract][Full Text] [Related]
2. The utility of FDG PET in diagnosis and follow-up of lymphoma in childhood. Sioka C Eur J Pediatr; 2013 Jun; 172(6):733-8. PubMed ID: 23559330 [TBL] [Abstract][Full Text] [Related]
3. 2-[18F]fluoro-2-deoxyglucose positron-emission tomography in staging, response evaluation, and treatment planning of lymphomas. Specht L Semin Radiat Oncol; 2007 Jul; 17(3):190-7. PubMed ID: 17591566 [TBL] [Abstract][Full Text] [Related]
4. Role of whole-body [18F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) and conventional techniques in the staging of patients with Hodgkin and aggressive non Hodgkin lymphoma. Pelosi E; Pregno P; Penna D; Deandreis D; Chiappella A; Limerutti G; Vitolo U; Mancini M; Bisi G; Gallo E Radiol Med; 2008 Jun; 113(4):578-90. PubMed ID: 18414808 [TBL] [Abstract][Full Text] [Related]
5. [(18)F]FDG in childhood lymphoma: clinical utility and impact on management. Montravers F; McNamara D; Landman-Parker J; Grahek D; Kerrou K; Younsi N; Wioland M; Leverger G; Talbot JN Eur J Nucl Med Mol Imaging; 2002 Sep; 29(9):1155-65. PubMed ID: 12192560 [TBL] [Abstract][Full Text] [Related]
6. Combined modality treatment for PET-positive non-Hodgkin lymphoma: favorable outcomes of combined modality treatment for patients with non-Hodgkin lymphoma and positive interim or postchemotherapy FDG-PET. Halasz LM; Jacene HA; Catalano PJ; Van den Abbeele AD; Lacasce A; Mauch PM; Ng AK Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e647-54. PubMed ID: 22607911 [TBL] [Abstract][Full Text] [Related]
7. FDG-PET/CT in lymphoma. Juweid ME Methods Mol Biol; 2011; 727():1-19. PubMed ID: 21331925 [TBL] [Abstract][Full Text] [Related]
8. [Comparison of findings with 18-FDG PET and CT in pretherapeutic staging of malignant lymphoma]. Thill R; Neuerburg J; Fabry U; Cremerius U; Wagenknecht G; Hellwig D; Osieka R; Günther R; Büll U Nuklearmedizin; 1997 Oct; 36(7):234-9. PubMed ID: 9441282 [TBL] [Abstract][Full Text] [Related]
10. Can fluorodeoxyglucose positron emission tomography/computed tomography avoid negative iliac crest biopsies in evaluation of marrow involvement by lymphoma at time of initial staging? Mittal BR; Manohar K; Malhotra P; Das R; Kashyap R; Bhattacharya A; Varma N; Varma S Leuk Lymphoma; 2011 Nov; 52(11):2111-6. PubMed ID: 21745169 [TBL] [Abstract][Full Text] [Related]
11. Staging in childhood lymphoma: differences between FDG-PET and CT. Hermann S; Wormanns D; Pixberg M; Hunold A; Heindel W; Jürgens H; Schober O; Franzius C Nuklearmedizin; 2005 Feb; 44(1):1-7. PubMed ID: 15711722 [TBL] [Abstract][Full Text] [Related]
12. [Computerized tomography and F-18-FDG positron emission tomography in staging of malignant lymphomas: a comparison]. Bumann D; de Wit M; Beyer W; Beese M; Lübeck M; Bücheler E; Clausen M Rofo; 1998 May; 168(5):457-65. PubMed ID: 9617362 [TBL] [Abstract][Full Text] [Related]
13. Accuracy of whole-body 18F-FDP-PET for restaging malignant lymphoma. Mikosch P; Gallowitsch HJ; Zinke-Cerwenka W; Heinisch M; Pipam W; Eibl M; Kresnik E; Unterweger O; Linkesch W; Lind P Acta Med Austriaca; 2003; 30(2):41-7. PubMed ID: 12752087 [TBL] [Abstract][Full Text] [Related]
14. Frequent impact of [18F]fluorodeoxyglucose positron emission tomography on the staging and management of patients with indolent non-Hodgkin's lymphoma. Blum RH; Seymour JF; Wirth A; MacManus M; Hicks RJ Clin Lymphoma; 2003 Jun; 4(1):43-9. PubMed ID: 12837154 [TBL] [Abstract][Full Text] [Related]
15. The role of FDG-PET imaging in the management of lymphoma. Kostakoglu L; Leonard JP; Coleman M; Goldsmith SJ Clin Adv Hematol Oncol; 2004 Feb; 2(2):115-21. PubMed ID: 16163171 [TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of the standardized uptake value of pre-therapeutic (18)F-FDG PET in patients with malignant lymphoma. Ahmadzadehfar H; Rodrigues M; Zakavi R; Knoll P; Mirzaei S Med Oncol; 2011 Dec; 28(4):1570-6. PubMed ID: 20524086 [TBL] [Abstract][Full Text] [Related]
17. Overview of early response assessment in lymphoma with FDG-PET. MacManus MP; Seymour JF; Hicks RJ Cancer Imaging; 2007; 7(1):10-8. PubMed ID: 17766210 [TBL] [Abstract][Full Text] [Related]
18. Tamayo P; Martín A; Díaz L; Cabrero M; García R; García-Talavera P; Caballero D Rev Esp Med Nucl Imagen Mol; 2017; 36(5):312-321. PubMed ID: 28483374 [TBL] [Abstract][Full Text] [Related]
19. Clinical impact of whole body FDG-PET on the staging and therapeutic decision making for malignant lymphoma. Sasaki M; Kuwabara Y; Koga H; Nakagawa M; Chen T; Kaneko K; Hayashi K; Nakamura K; Masuda K Ann Nucl Med; 2002 Jul; 16(5):337-45. PubMed ID: 12230093 [TBL] [Abstract][Full Text] [Related]
20. Staging, response to therapy, and restaging of lymphomas with 18F-FDG PET. Altamirano J; Esparza JR; de la Garza Salazar J; Calvo PS; Vera SR; Chalapud Revelo JR; Estrada G Arch Med Res; 2008 Jan; 39(1):69-77. PubMed ID: 18067998 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]